Estudo da interação de diferentes antibacterianos em linhagens de Escherichia coli uropatogênicas

Alana Fernanda Silva de Aquino, Rômulo Maia Ferreira, Andrea de Souza Monteiro, Joao Luis Damião Caldoncelli

Resumo


A combinação de agentes antimicrobianos disponíveis para o tratamento de infecção do trato urinário causadas por Escherichia coli uropatogênicas tem sido investigada a fim de aumentar a eficácia dos tratamentos. Determinar o perfil de suscetibilidade de isolados uropatogênicas frente a vários antimicrobianos e a eficácia da interação de antimicrobianos. Neste estudo foram avaliadas 39 linhagens de uropatogênicas pelos testes de difusão de antimicrobianos em discos, determinação da concentração inibitória mínima dos antimicrobianos e análise da combinação das drogas antimicrobianas. Os dados obtidos foram submetidos à análise de variância (ANOVA) e as médias comparadas pelo teste de Tukey. As resistências mais significativas foram às classes de tetraciclinas e as cefalosporinas de primeira geração pelo método de disco difusão e sistema VITEK. No método de Checkerboard, a associação entre a cefalotina/norfloxacina e gentamicina/ofloxacina, obtiveram sinergismo em todos os isolados testados. Assim, a associação de antimicrobianos pode ser uma alternativa para o tratamento de infecção do trato urinário, assim como de outras infecções diminuindo a possibilidade de falha terapêutica.

 

Palavras-chave: Agentes Antibacterianos; Infecções Urinárias; Sinergismo Farmacológico

 


Texto completo:

PDF

Referências


Russo TA, Johnson JR, Proposal for a new inclusive designation for extraintestinal pathogenic isolates of E. coli: ExPEC. J. Infect. Dis. 181:1753-1754,2000.

Schilling, JD, Mulvey MA, Hultgren SJ. Structure and function of E. coli type 1 pili: new insight into the pathogenesis ofurinary tract infections. J. Infect. Dis. 183(Suppl. 1):S36–S40, 2001.

Marrs CF, Zhang L, Foxman B. E. coli mediated urinary tract infections: are there distinct uropatogenic E. coli(UPEC) pathotypes?. FEMS Microbiol. Lett. 252;183-190,2005.

Brzuszkiewicz E, Bruggemann H, Liesegang H, Emmerth M, Olschlager T, Nagy G, Albermann K, Wagner C, Buchrieser C, Emody L, Gottschalk G, Hacker J, Dobrindt U. How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic E. coli strains. Proc. Natl. Acad. Sci. USA. 2006; 103:12879-84.

Obaid JMAS. Uropathogenic E. coli isolates with different virulence genes content exhibit similar pathologic influence on vero cells. Polish J. Microbiol. 2014; 63(1):43-49.

Narciso A, Lito L, Cristino JM, Duarte A. Escherichia coli uropatogênicas. Resistência aos antibióticos versus fatores de virulência. Acta Urol. . 11-20. 2010

Gupta K. Increasing antimicrobial resistance and the management of uncomplicated comunity-acquired urinary tract infections. Ann. Intern. Med. V. 2001;135(1): 41-50.

Culler HF. Formação de biofilme por E. coli Enteropatogênica Atípica. Dissertação de Mestrado em Biotecnologia. São Paulo: Universidade de São Paulo - Instituto de Biotecnologia de São Carlos. 2010.

Hultgren SJ, Mysorekar IU. Mechanisms of uropathogenic E. coli persistence and eradication from the urinary tract. PNAS. 2006; 103(38): 14170-175.

Chanda S, Rakholya K. Combination therapy: Synergism between natural plant extracts and antibiotics against infectious diseases. Science against microbial. Pathogens: Communicating current research and technological advances. 2011; 1(13): 520-29.

Bauer AW , Kirby WM , Sherris JC , Turck M . Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493-6.

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests. Clinical and Laboratory Standards Institute, WAYNE, P.A.: CLSI,2005

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests. Clinical and Laboratory Standards Institute, WAYNE, P.A.: CLSI,2003

Schwalbe R, Steele-moore L, Goodwin AC. Antimicrobial susceptibility testing protocols. Boca Raton: Taylor e Francis, 2007. P.275-299.

Odds FC. Synergy, antagonism and what the Checkerboard puts between them. J. Antimicrob. Chemother.52(1):1.2003.

Hardman J, Limbird L. Goodman & Gilman. As Bases Farmacológicas da Terapêutica, 10 ed., Rio de Janeiro, MacGraw Hill, 2003.

Ribas RM, Filho PGP, Cezario RC, Silva PF, Lanconi DPP, Duque AS. Fatores de risco para colonização por bactérias hospitalares multirresistentes em pacientes críticos e clínicos em um Hospital Universitário Brasileiro. Rev. Med. Minas Gerais, 19(3):193-197,2009.

Niranjan V, Malini A. Antimicrobial resistence pattern in E. coli causing urinary tract infection among impatients. Indian J. Med. Res. 2014; 139(6): 945-8.

ANVISA. Antimicrobianos- Bases teóricas e uso clínico. 2007

Rodrigues TM, Grieco AS, Simoes FA, Castilho LN. Como diagnosticar e tratar infecção urinaria. RBM, vol. 67, 2010.

Spinosa HS, Gorniak SL, Bernardi MM. Farmacologia aplicada a medicina veterinária. Editora Guanabara Koogan, Quarta edição,2006.

White RL, Burgess DS, Manduru M, Bosso JÁ. Comparison of three different in vitro methods of detecting synergy: Timekill, Checkerboard And E-Test. Antimicrob. Agents Chemother., 40(8): 1914-18, 1997.

Jung R, Husain M, Choi MK, Fish DN. Synergistic activies of moxifloxacin combined with piperaciclin-tazobactan or cefepime against Klebisiella pneumonia, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates. Antimicrob. Agents Chemother,2004; 48(3): 1055-1057.

Bassetti M, Righi E, Rosso R, Manelli S, Di Biaggio A, Fasce R. Efficacy of the combination of levofloxacinplus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit. Int J. Antimicrob. Agents. 2006;28:582-585.

Sweeney MT, Brumbaugh GW, Watts JL. In vitro activies of tulathromycin and ceftiofur combined with other antimicrobial agents using bovine P. multocida and M. haemolytica isolates. Veterinary Therapeutics . Vol. 9, Number 3, 212-222, 2008.

Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistent strain of P. aeruginosa and A. baumannii isolated from intensive care units. Int. J. Antimicrob. Agents.2006;27:224-228.

Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistent P. aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother.2003;47:905-909.

Song W, Woo HJ, Kim JS, Lee KM.. In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of P. aeruginosa . Int. J. Antimicrob. Agents. 2003; 21:8-12.

Davis MA, Isenberg HD, France KA, Jenkings SG. In vitro activity of gatifloxacin alone and in combination with cefepime ,meropenem, piperacilin and gentamicin against multidrug-resistent organisms. J. Antimicrob. Chemother 2003; 51:1203-1211.

Drago L, De Vecchi E, Nicola L, Gismondo MR. In vitro evaluation of antibiotics combinations for empirical therapy of suspected methicillin resistant S. aureus severe respiratory infections. BMC Infectious Diseases. 2007; 1-7.

Pillai SK, Moellering RC, Eliopoulos G. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 5th ed. Baltimore: Williams & Wilkins, 365-440., 2005.

Diez EM. In vitro activity of aztreonam ,cefotaxim , ceftazidime and imipenem combined with ciprofloxacin against Gram negative bacilli and compared with amikacin combinations against P. aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 1991;10: 90-92.

Iroha IR, Amadi ES, Orji JO, Ogabus AC, Oji AE, Esimone CO. The interaction between gentamicin and floroquinolones against ESBL producing clinical isolates of E. coli. Trends in Medial Reseach. 2008; 3: 90-94.

Bajaksouzian S. Activies of levofloxacin, ofloxacin and ciprofloxacin, alone or in combination with amikacin, against acinetobacters as determined by checkerboard and time kill studies. Antimicrob. Agents Chemother 1997;41:1073-1076.

Hayami H, Goto T, Kawahara M. Activies of beta-lactams , fluorquinolones, amikacin and fosfomycinalone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections. J. Infect. Chemother 1999; 5:130-138.

Spoorthi NJ, Vishwanatha T, Reena V, Divyashree BC, Aishwarya S, Siddhalingeshwara KG, Venugopal N, Ramesh I. Antibiotic synergy test: Checkerboard method on multidrug resistant Pseudomonas aeruginosa. International Research Journal of Pharmacy.2011,2(12),196-198.

Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ. In vitro activity of ceftaroline alone and in combinations against clinical isolates of resistant gram-negative pathogens , including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents and Chemotherapy, 2009, p.2360 - 2366.

Schaadt RD, Sweeney DA, Biek D, Zurenko GE. In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents, abstr.E-279. Progr. Abstr. 47th Intersci. Conf. Antimicrob.

Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by E test and Checkerboard Methods of Antimicrobial Combinations against Brucellamelitensis. J. of Clinical Microb. 2004:vol 43, número 1; 140-143.

Sweeney MT, Brumbaugh GW, Watts JL. In vitro activies of tulathromycin and ceftiofur combined with other antimicrobial agents using bovine P. multocida and M. haemolytica isolates. Veterinary Therapeutics. Vol. 9, Number 3, 212-222, 2008.




DOI: https://doi.org/10.24863/rib.v9i2.137

Apontamentos

  • Não há apontamentos.